The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (preterm infants, infants with chronic lung di...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanari, Marcello, Vandini, Silvia, Arcuri, Santo, Galletti, Silvia, Faldella, Giacomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693113/
https://www.ncbi.nlm.nih.gov/pubmed/23840240
http://dx.doi.org/10.1155/2013/359683
_version_ 1782274707326763008
author Lanari, Marcello
Vandini, Silvia
Arcuri, Santo
Galletti, Silvia
Faldella, Giacomo
author_facet Lanari, Marcello
Vandini, Silvia
Arcuri, Santo
Galletti, Silvia
Faldella, Giacomo
author_sort Lanari, Marcello
collection PubMed
description Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (preterm infants, infants with chronic lung disease or congenital heart disease) at high risk of severe and potentially lethal course of the infection. This drug was reported to be safe, well tolerated and effective to decrease the hospitalization rate and mortality in these groups of infants by several clinical trials. In the present paper we report the development and the current use of monoclonal antibodies for prophylaxis against respiratory syncytial virus.
format Online
Article
Text
id pubmed-3693113
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36931132013-07-09 The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection Lanari, Marcello Vandini, Silvia Arcuri, Santo Galletti, Silvia Faldella, Giacomo Clin Dev Immunol Review Article Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (preterm infants, infants with chronic lung disease or congenital heart disease) at high risk of severe and potentially lethal course of the infection. This drug was reported to be safe, well tolerated and effective to decrease the hospitalization rate and mortality in these groups of infants by several clinical trials. In the present paper we report the development and the current use of monoclonal antibodies for prophylaxis against respiratory syncytial virus. Hindawi Publishing Corporation 2013 2013-06-11 /pmc/articles/PMC3693113/ /pubmed/23840240 http://dx.doi.org/10.1155/2013/359683 Text en Copyright © 2013 Marcello Lanari et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Lanari, Marcello
Vandini, Silvia
Arcuri, Santo
Galletti, Silvia
Faldella, Giacomo
The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
title The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
title_full The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
title_fullStr The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
title_full_unstemmed The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
title_short The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
title_sort use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693113/
https://www.ncbi.nlm.nih.gov/pubmed/23840240
http://dx.doi.org/10.1155/2013/359683
work_keys_str_mv AT lanarimarcello theuseofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT vandinisilvia theuseofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT arcurisanto theuseofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT gallettisilvia theuseofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT faldellagiacomo theuseofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT lanarimarcello useofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT vandinisilvia useofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT arcurisanto useofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT gallettisilvia useofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection
AT faldellagiacomo useofhumanizedmonoclonalantibodiesforthepreventionofrespiratorysyncytialvirusinfection

Ejemplares similares